ClinicalTrials.gg
RecruitingNCT05917925COLARTUpdated Jul 6, 2023

Evaluation of the Effect of a Food Supplement Based on Hydrolyzed Collagen on Joint Function.

An interventional study of COLLAGEN (COL) and PLACEBO (PLA) in Pain, Acute, Pain, Chronic and Knee Osteoarthritis, sponsored by Francisco Javier Martínez Noguera. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-06.

Sponsored by Francisco Javier Martínez Noguera · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Acute Pain with a site in Spain — 4 open to participants now, 5 under way, none of them phase 3. Acute Pain · Spain.

Planned enrollment
12th of 19
80 · median 160
Started
2023
with 2 others
No phase
11 of 20
4 open now
Registered
15th of 20
by date
Lead sponsor
1 of 20
Francisco Javier Martínez Noguera

Among the 20 studies in Acute Pain with a site in Spain, this one is the 12th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2023, is one of 11 with no phase, and was the 15th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

4 of the 20 studies in Acute Pain with a site in Spain are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Acute Pain with a site in Spain, or all of them as a file.
02

Study summary

This clinical study evaluates the effect of taking a hydrolyzed collagen-based supplement on pain, function and quality of life in a moderately physically active population. Non-pathological knee pain is a common occurrence in many healthy people and can limit the quality of life. Therefore, the resolution of this problem can bring many benefits in terms of quality of life.

Read the detailed description

Study design

Randomized, double-blind, placebo-controlled clinical trial with 2 parallel study groups (collagen-based formulation and placebo). Participants will take the study products for 12 weeks.

03

Conditions studied

  • Pain, Acute
  • Pain, Chronic
  • Knee Osteoarthritis
  • Knee Injuries

Keywords

  • Hydrolyzed collagen
  • Post-exercise pain
  • Supplementation
  • Inflammation
  • Quality of life
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals who exercise regularly and meet the WHO definition of being moderately active.
  • Persistent exercise-associated knee pain lasting at least 2 months prior to study inclusion.
  • Knee pain score on the visual analogue pain scale of at least 30 mm, taking into account that the scale has a maximum range of 100 mm.

Exclusion criteria

Exclusion Criteria:

  • Individuals with severe illness.
  • Subjects who are taking or have been treated within the last 7 days with glucosamine, chondroitin sulphate, collagen or hyaluronic acid injections or any dietary supplement indicated for joint health.
  • Subjects with chronic inflammatory diseases affecting the musculoskeletal apparatus.
  • Subjects with obesity ( ≥ 30 Kg/m2).
  • Allergy or known to any of the ingredients in the product.
  • Phenylketonuria.
  • Treatment with narcotics, steroidal anti-inflammatory drugs or . - Symptoms of extreme pain requiring high doses of analgesic therapy for a period of time longer than 2 weeks or intra-articular injection treatment.
  • Individuals with diabetes.
  • Pregnant women.
  • Lactating women.
  • Subjects who are participating in a clinical trial.
  • Subjects who have participated in a clinical trial for pain in the last month.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    COLLAGEN (COL)

    Subjects in this group will intake 10 g/day of a hydrolyzed collagen-based supplement.

    Dietary Supplement: COLLAGEN (COL)

  • Placebo comparator
    PLACEBO (PLA)

    Subjects in this group will intake 10 g/day of placebo (maltodextrin).

    Dietary Supplement: PLACEBO (PLA)

Interventions

  • Dietary supplementCollagenStudies of CollagenCollagen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The collagen-based supplement will be ingested every day for 12 weeks at the same time.

  • Dietary supplementPLACEBO (PLA)

    The placebo will be ingested every day for 12 weeks at the same time.

06

What researchers measure

Primary outcomes

  1. Intensity of knee pain

    It will be measured using a 100 mm long horizontal visual analogue scale (VAS) on which the participant must mark the pain he/she feels with 0 being "none" and 100 being "the most intense pain he/she can imagine". Once the level of pain is marked on the horizontal line, the length is measured from 0 in millimetres with a millimetre ruler. The results will be evaluated according to three levels of pain based on the marked values: \<40 mm: Values below 40 mm indicate mild or mild moderate pain 40-60 mm: If the measurement is between 40 and 60 mm, the pain is considered moderate to moderate-severe \>60 mm: If the values are greater than 60 mm, the pain is considered severe to unbearable.

    Time frame: Throughout study completion, an average of 12 weeks

Secondary outcomes

  1. Physical activity data

    Intensity by applying the IPAQ questionnaire and type (running, cycling, climbing, tennis, football...).

    Time frame: The following data will be recorded during the baseline visit

  2. Demographic data

    Age, sex, employment status (active, unemployed, retired, student ....).

    Time frame: The following data will be recorded during the baseline visit

  3. Frequency of alcohol and tobacco consumption

    Alcohol consumption and tobacco consumption (grams of alcohol and cigarettes per week)

    Time frame: The following data will be recorded during the baseline visit

  4. Weight

    It will be measured by means of a precision balance (kg)

    Time frame: The following data will be recorded during the baseline visit

  5. Height

    It will be measured by means of a stadiometer (cm)

    Time frame: The following data will be recorded during the baseline visit

  6. Body mass index

    It will be calculated by the following formula kg/m2

    Time frame: The following data will be recorded during the baseline visit

  7. Clinical data

    Symptoms are unilateral (Yes/No), Other joint problems (back, hand, neck, feet, shoulder, hip)

    Time frame: The following data will be recorded during the baseline visit

  8. Current analgesic medication:

    Medication that has been taken at least once a week during the previous month. The name or active ingredient of the drug, dosage and frequency should be indicated.

    Time frame: The following data will be recorded during the baseline visit

  9. Number of participants taking medication

    During the study, both the increase or reduction of chronic analgesic medication taken by the participant for pain management and the intake of new rescue medication, which is medication taken occasionally for symptomatic or symptom management, treatment of crises or exacerbations, will be recorded.

    Time frame: Throughout study completion, an average of 12 weeks

  10. Knee range of motion (ROM)

    To assess ROM, the participant will be placed in a prone position on a stretcher. An electrogoniometer will then be placed on the leg to be assessed (affected leg) and the participant will be asked to voluntarily flex as far as possible or until pain is felt.

    Time frame: Throughout study completion, an average of 12 weeks

  11. WOMAC scale to measure pain, functional capacity and impact on quality of life

    The WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) questionnaire is used to assess participants' perceived clinical changes in knee pain, stiffness and function.

    Time frame: Throughout study completion, an average of 12 weeks

  12. Quality of Life Questionnaire SF-36

    The SF-36 health questionnaire is composed of 36 items that aim to collect all relevant aspects to characterize the health of an individual.

    Time frame: Throughout study completion, an average of 12 weeks

  13. KOOS Questionnaire for Knee Assessment

    The Knee Injury and Osteoarthritis Outcome Score (KOOS) has been developed as an instrument to assess the patient's opinion of their knee and associated problems. The scores for each dimension are calculated by summing the responses to the relevant questions. The resulting scores are transformed into a scale from 0 to 100.

    Time frame: Throughout study completion, an average of 12 weeks

  14. Sleep quality using the Pittsburgh test

    Sleep quality is assessed using the Pittsburgh sleep quality questionnaire. This questionnaire has 19 self-assessment questions and 5 questions addressed to the roommate or bed partner, with only the first 19 being used to obtain the overall score.

    Time frame: Throughout study completion, an average of 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Research Center for High Performance Sport. Catholic University of Murcia
    La Ñora, Murcia 30830, Spain
    Recruiting
08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Feb 2024, 10 months after the start.

Of 425 non-industry interventional studies with no phase under Acute Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 10 months is below that.

Counting every sponsor, half of 431 studies reached it within 11 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Jun 26, 2023
StartActual
Apr 1, 2023
Primary completionEst.
Feb 2024
CompletionEst.
Jun 2024
Last update
Jul 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05917925
Lead sponsor
Francisco Javier Martínez Noguera
Collaborators
San Antonio Technologies - San Antonio Catholic University of Murcia
Responsible party
Francisco Javier Martínez Noguera (PhD (Head of the nutrition area of the Research Center for High Performance Sport), Universidad Católica San Antonio de Murcia) — Sponsor-investigator
First posted
Jun 26, 2023
Start date
Apr 1, 2023
Primary completion
Feb 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Jul 6, 2023

Study contacts

Francisco Javier Martínez Noguera, PhD
Contact
fjmartinez3@ucam.edu
968278566 ext. +34
Cristian Marín Pagán, PhD
Contact
cmarin@ucam.edu
968278566 ext. +34
Francisco Javier Martínez Noguera, PhD
study chair · Research Center for High Performance Sport. Catholic University of Murcia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Collagen

Start the discussion